More information about AXSOME THERAPEUTICS INC.

We aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated medicines that expand the treatment options available to caregivers and improve the lives of patients living with CNS disorders. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications. Pipelin Axsome Therapeutics is building a portfolio of differentiated product candidates that address unmet medical needs. Some of our product candidates combine multiple mechanisms of action to produce novel medicines that address deficiencies of current approaches. The company’s current pipeline includes two late-stage product candidates and one preclinical candidate.